Arcellx Inc Cash Flow Conversion Efficiency
Arcellx Inc cash flow conversion efficiency. Based on the latest financial reports, Arcellx Inc (ACLX) has a cash flow conversion efficiency ratio of -0.145x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.17 Million) by net assets ($402.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ACLX market cap overview for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Arcellx Inc (2018–2025)
Cash flow conversion efficiency of Arcellx Inc from 2018 to 2025. This chart illustrates how Arcellx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Arcellx Inc for real-time trading data and today's change.
Arcellx Inc Cash Flow Conversion Ratio Explained
Arcellx Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arcellx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcellx Inc ranked by their cash flow conversion efficiency. Review ACLX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank of Maharashtra
NSE:MAHABANK
|
-0.678x |
|
Gaztransport & Technigaz SAS
PA:GTT
|
0.372x |
|
NINGBO SHANSHAN GDR/A
F:OJ8
|
N/A |
|
Hongfa Technology Co Ltd
SHG:600885
|
0.046x |
|
Hyundai Heavy Industries Holdings Co Ltd
KO:267250
|
0.075x |
|
Sibanye Stillwater Limited
F:47VS
|
0.096x |
|
Shenzhen Sunway Communication
SHE:300136
|
0.034x |
|
Lotes Co Ltd
TW:3533
|
0.037x |
Annual Cash Flow Conversion Efficiency for Arcellx Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Arcellx Inc from 2018 to 2025. Also see ACLX total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $402.35 Million | $-210.26 Million | -0.523x | -184.74% |
| 2024-12-31 | $454.79 Million | $-83.47 Million | -0.184x | -142.92% |
| 2023-12-31 | $485.38 Million | $207.57 Million | 0.428x | +188.26% |
| 2022-12-31 | $204.95 Million | $-99.30 Million | -0.485x | -208.55% |
| 2021-12-31 | $-121.52 Million | $-54.24 Million | 0.446x | +178.71% |
| 2020-12-31 | $50.54 Million | $-28.66 Million | -0.567x | -198.90% |
| 2019-12-31 | $-32.74 Million | $-18.77 Million | 0.573x | +216.97% |
| 2018-12-31 | $14.00 Million | $-6.86 Million | -0.490x | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more